Video

Examining Response Rates in MSI-H and NTRK Fusion GI Cancers

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

Finding these biomarkers in patients with GI cancers can be particularly important, as it can help choose a treatment plan that can have a dramatic response in this group of patients.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Doug
Image of doctor.
Image of Dr. Kelly
Image of Dr. Boffa.
Immune Therapy Expands Melanoma Treatment to More Patients
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
image of doctor D'Sa
Image of Dr. Eng.
Related Content